Decaf vs Caffeinated Coffee
The decaffeinated coffee market exists for a real clinical reason — somewhere between 15 and 35% of adults have a meaningful medical reason to limit caffeine intake (pregnancy, panic-disorder anxiety, atrial fibrillation, slow CYP1A2 metabolism, severe insomnia), and many of those people still want the polyphenol intake and the social ritual of drinking coffee. Decaf is not zero-caffeine — FDA regulations allow up to 0.10% residual caffeine on a dry basis, translating to 2-15 mg of caffeine per brewed cup vs 80-200 mg for regular. Four decaffeination processes dominate the industry, with substantially different effects on flavor and chlorogenic acid retention: Swiss Water, supercritical CO2, ethyl acetate, and methylene chloride. Most CGA-mediated benefits (type 2 diabetes protection, postprandial glucose attenuation, liver protection, gut microbiome support) survive decaffeination. Most caffeine-driven benefits (cognitive alertness, ergogenic performance, Parkinson's protection) do not. This page maps the four decaf processes, the residual caffeine math, which benefits survive, and the practical decision rules for who should be drinking decaf and when.
Table of Contents
- Why Decaf Exists — the Medical Use Cases
- Decaf Is Not Zero Caffeine
- Swiss Water Process
- Supercritical CO2 Process
- Ethyl Acetate ("Natural" Decaf)
- Methylene Chloride Process
- CGA and Flavor Retention Across the Four Processes
- Benefits That Survive Decaffeination
- Benefits That Do Not Survive Decaffeination
- Decaf in Pregnancy
- Decaf for Sleep Disorders and Anxiety
- Decaf for Hypertension, Arrhythmia, and Slow Metabolizers
- The Half-Caf Strategy
- Key Research Papers
- Connections
Why Decaf Exists — the Medical Use Cases
Decaf has a poor reputation among coffee enthusiasts and is often viewed as a flavor-compromised substitute for the "real thing." That framing misses the substantial population for whom decaf is the correct beverage choice for medical reasons. The major use cases:
- Pregnancy — ACOG and most national obstetric societies recommend limiting caffeine to under 200 mg/day during pregnancy due to associations with low birth weight, miscarriage, and pregnancy loss in higher-intake observational studies. A pregnant woman who drinks 2-3 cups of coffee daily exceeds this limit and either needs to cut back or shift to decaf. Approximately 4 million pregnancies occur annually in the United States; the decaf market for pregnancy alone is large.
- Panic disorder and severe anxiety — caffeine reliably triggers panic attacks in panic-disorder patients at doses (300-450 mg) that affect controls minimally. Panic-disorder patients are typically advised to limit or eliminate caffeine. Decaf preserves the social and ritual aspects of coffee without the panic-provoking pharmacology. See Anxiety for more.
- Atrial fibrillation and other arrhythmias — the relationship between coffee and arrhythmia is complex (most observational studies find no significant association in light-to-moderate drinkers, and some find protection), but for patients with known atrial fibrillation who notice palpitations after caffeine, decaf is the conservative choice. The European Society of Cardiology guidance is generally permissive about coffee in AF patients, but individual sensitivity varies.
- Severe insomnia — patients with established insomnia who cannot tolerate even morning caffeine due to prolonged half-life or extreme sensitivity benefit from decaf throughout the day or from switching to decaf after noon.
- Slow CYP1A2 metabolizers — the ~55% of the population with the AC or CC genotype at rs762551 metabolize caffeine slowly enough that a single morning cup can produce 8-12 hours of measurable effect. For people whose phenotype matches (described as "coffee makes me wired" or "I can't handle even half a cup"), decaf preserves the polyphenol and ritual benefits without the prolonged caffeine load. See the Cognitive Performance page CYP1A2 section.
- GERD — both caffeinated and decaffeinated coffee can trigger reflux symptoms (coffee acidity and lower esophageal sphincter relaxation are partly caffeine-independent), but caffeinated coffee is worse in most patients. Decaf is a reasonable first-line modification for mild reflux. Cold brew and dark-roast decaf are typically best tolerated.
- Adolescents — the American Academy of Pediatrics advises against routine caffeine consumption in adolescents under 18, recommending no more than 100 mg/day for children 12-18. Teen coffee drinkers who want the experience and polyphenol intake without the caffeine load can use decaf.
- Elderly patients with anxiety or sleep disorders — caffeine sensitivity tends to increase with age due to slower metabolism and increased autonomic reactivity. Many elderly patients tolerate decaf well even when they cannot tolerate caffeinated.
The combined population with one or more of these medical reasons easily reaches 15-35% of adults at any given time, more if the broad "caffeine sensitivity" category is included. The decaf market exists for substantive reasons.
Decaf Is Not Zero Caffeine
FDA regulations under 21 CFR 161.158 require decaffeinated coffee to contain no more than 0.10% caffeine by weight on a dry basis. EU regulations are slightly tighter (0.1% for roast and ground, 0.3% for instant). These limits translate to:
- A 240 mL cup of brewed decaf typically contains 2-15 mg of caffeine.
- The same cup of regular coffee contains 80-200 mg.
- So decaf delivers roughly 2-10% of the caffeine of regular coffee, depending on the decaf brand and the regular comparator.
For most adults, 2-15 mg of caffeine is pharmacologically insignificant — the threshold for measurable cognitive effects is around 30-50 mg. For pregnant women with a 200 mg/day cap, decaf is well within the limit even at 5 cups a day. For very caffeine-sensitive patients (severe panic disorder, severe insomnia, certain arrhythmias), the residual caffeine in decaf can still produce noticeable effects in a subset of patients — switching to herbal infusions (chamomile, peppermint, rooibos) may be needed in the most sensitive cases.
The residual caffeine content varies meaningfully across brands and processes. Independent testing by Consumer Reports and others has found:
- Starbucks decaf (CO2 process): 12-25 mg per 16 oz serving
- Folgers decaf (methylene chloride): 8-15 mg per 8 oz cup
- Swiss Water Process decafs (various brands): 1-7 mg per 8 oz cup, generally the lowest residual
- Some "swiss water" decafs from grocery store private labels: 5-15 mg, suggesting actual process varies
- Instant decaf: typically 3-8 mg per 8 oz reconstituted
For patients who need the absolute minimum residual caffeine, Swiss Water Process decafs with explicit residual-caffeine claims on the label are the safest choice.
Swiss Water Process
Developed in Switzerland in the 1930s and commercialized at scale by Swiss Water Decaffeinated Coffee Inc. in British Columbia, this is the only major decaffeination process that uses no chemical solvents at any step.
Process overview:
- A batch of green coffee beans is soaked in hot water to dissolve caffeine plus most of the other water-soluble compounds (CGAs, sugars, soluble proteins, etc.).
- The resulting liquid (called "Green Coffee Extract," GCE) is passed through activated carbon filters with pore size selected to retain caffeine while letting CGAs and flavor compounds pass through.
- The de-caffeinated GCE, now saturated with CGAs and flavor compounds but stripped of caffeine, is used to soak a fresh batch of green beans. Because the GCE is already saturated with all the non-caffeine soluble compounds, the only thing the new beans lose to the water is their caffeine.
- The new beans, now decaffeinated, are dried and shipped. The GCE is filtered through activated carbon again and reused on the next batch.
Result: 99.9% caffeine removal, with most CGAs, sugars, and flavor compounds retained because they were already in solution equilibrium and did not need to leave the bean.
Advantages:
- No chemical solvent residue. Suitable for organic and chemical-free designations.
- Best CGA retention among the four major processes (typically 80-90% of original CGA content).
- Good flavor retention; Swiss Water decafs are widely viewed as the best-tasting decafs.
- Low residual caffeine, with the company claiming 99.9% removal (typically 1-5 mg residual per cup).
Disadvantages:
- More expensive than solvent-based methods, both in capital equipment and process cost. This is reflected in the higher retail price of Swiss Water decafs.
- Process is slower (typically 8-10 hours per batch).
Swiss Water Process is the default recommendation for patients who want a high-quality decaf with no solvent concerns. Look for the explicit "Swiss Water Process" or "SWP" designation on the package — the term "water process" without "Swiss" may refer to other water-based processes with different specifications.
Supercritical CO2 Process
Developed in Germany in the 1970s by Kurt Zosel. Uses CO2 at supercritical conditions (above 31°C and 74 bars pressure, where the gas-liquid distinction disappears) as a selective solvent for caffeine.
Process overview:
- Green beans are softened with steam to open pore structure.
- The beans are placed in a high-pressure vessel and supercritical CO2 is circulated through them. At supercritical conditions, CO2 selectively dissolves caffeine while leaving most flavor compounds (which are non-polar or polar with hydrogen-bonding character) largely intact.
- The caffeine-laden CO2 is decompressed and the caffeine precipitates out. The CO2 is reused.
- The decaffeinated beans are dried and shipped. The recovered caffeine is sold to the pharmaceutical and soft-drink industries.
Result: ~97% caffeine removal. Better CGA and flavor retention than chemical solvent methods (because CO2 is selective for caffeine vs the larger polar molecules).
Advantages:
- No chemical solvent residue (CO2 itself is benign and present in trace amounts in the final bean).
- Good CGA retention (typically 70-85% of original).
- Reasonable flavor retention.
- Highly scalable; suited to large industrial operations. Most major commodity decaf production (Maxwell House, Folgers premium, Starbucks decaf) uses CO2.
Disadvantages:
- Higher capital cost (high-pressure equipment).
- Slightly less selective than Swiss Water for caffeine vs other compounds, so flavor retention is marginally lower than SWP.
CO2 process is the "mass market chemical-free" option, widely available at moderate price points. It is the dominant process for Starbucks decaf and many other major brands.
Ethyl Acetate ("Natural" Decaf)
Uses ethyl acetate as the caffeine solvent. Ethyl acetate is a small organic molecule (CH3-COO-CH2-CH3) that occurs naturally in many fruits, particularly bananas and apples (responsible for some of their characteristic aroma). When marketed as "natural decaf," the ethyl acetate is sometimes derived from natural sources (sugarcane fermentation in Colombia is a common source), although the chemical itself is identical whether from natural or synthetic origin.
Process overview:
- Green beans are softened with steam.
- The beans are soaked in or circulated with ethyl acetate, which selectively extracts caffeine.
- The caffeine-laden ethyl acetate is removed and the beans are steamed to remove residual ethyl acetate.
- The decaffeinated beans are dried and shipped.
Result: ~97% caffeine removal. Moderate flavor retention.
Advantages:
- Lower capital cost than CO2 process.
- The "natural" designation when sugarcane-derived ethyl acetate is used is a marketing advantage in some markets, particularly Latin American and specialty-coffee markets.
- Process is well established and reliable.
Disadvantages:
- Some loss of the more volatile flavor compounds compared to Swiss Water or CO2.
- Residual ethyl acetate is detectable in trace amounts (within FDA limits of 2 ppm) in some samples. Although the residue is harmless and ethyl acetate is GRAS-classified, the "solvent" perception affects some consumers.
- CGA retention typically 65-80%, slightly lower than CO2 or SWP.
Ethyl acetate decaf is common in Colombian specialty decaf offerings and in some premium organic decaf brands. The "sugar cane decaf" label often indicates ethyl acetate process from sugarcane-derived solvent.
Methylene Chloride Process
The oldest commercial decaffeination process, developed in the early 1900s by Ludwig Roselius (Kaffee HAG). Uses dichloromethane (methylene chloride, CH2Cl2) as the caffeine solvent.
Process overview is similar to ethyl acetate, with methylene chloride substituted as the solvent. The methylene chloride has higher selectivity for caffeine than ethyl acetate, generally producing better flavor retention. Residual methylene chloride in the beans is volatile and is largely evaporated during roasting (boiling point 39.6°C, vs roasting temperature of 196-235°C).
Result: ~97% caffeine removal. Best flavor retention among solvent-based methods, often considered indistinguishable from regular coffee by sensory panels at the higher quality tier.
Advantages:
- Lower cost than Swiss Water or CO2.
- Excellent flavor retention.
- Highly selective for caffeine vs other compounds, so good CGA retention (70-85%).
- Well-established process used by most low-cost commodity decaf brands.
Controversies and safety:
- Methylene chloride is on the IARC Group 2A list (probably carcinogenic to humans) based on animal carcinogenicity studies.
- FDA limits residual methylene chloride in decaf coffee to 10 ppm. Independent testing of commercial decaf typically finds residuals well below this limit (often less than 1 ppm and frequently undetectable).
- The EU EFSA reviewed methylene chloride decaf in 2023 and concluded that consumer exposure is well below health-based guidance values.
- In January 2024, the FDA proposed banning methylene chloride from food processing applications including coffee decaffeination, with implementation in 2026-2027. The Clean Label Project and a coalition of advocacy groups had petitioned for this change. The proposed rule was pending finalization at the time of this writing.
- Major brands have been transitioning away from methylene chloride preemptively. Maxwell House transitioned to ethyl acetate in 2023; Folgers, Nescafe, and others are reformulating.
The practical assessment: the actual health risk from methylene chloride residue in commercially produced decaf coffee is small, based on the trace residual amounts and the volatility-driven loss during roasting. The advocacy and regulatory pressure is driven more by precautionary principle (because chemical-free alternatives exist, why use a probable carcinogen at all) than by demonstrated harm in the coffee context. For consumers who want to avoid the issue entirely, choose Swiss Water, CO2, or ethyl acetate decaf with explicit process labels.
CGA and Flavor Retention Across the Four Processes
Approximate ranking of the four processes for CGA retention, residual solvent concerns, and flavor preservation:
- Swiss Water Process — best CGA retention (80-90%), no solvent concerns, very good flavor. Most expensive at retail.
- Supercritical CO2 — very good CGA retention (70-85%), no solvent concerns, good flavor. Mid-to-high retail price.
- Methylene chloride — good CGA retention (70-85%), regulatory uncertainty / advocacy concern despite small actual residue, excellent flavor. Lowest retail price.
- Ethyl acetate — moderate CGA retention (65-80%), no major solvent concerns, moderate flavor retention. Mid-range retail price.
For health-focused consumers, the order is Swiss Water > CO2 > ethyl acetate > methylene chloride. For flavor-focused consumers, the order shifts to Swiss Water = methylene chloride > CO2 > ethyl acetate. For the "cheap decaf for office break room" use case, methylene chloride still dominates although that is changing rapidly.
Across all four processes, decaf delivers 65-90% of the CGA content of equivalent regular coffee at equivalent roast level. The non-caffeine polyphenol benefits are substantially preserved — this is the strongest argument for decaf as a health-protective beverage choice.
Benefits That Survive Decaffeination
The following coffee benefits are preserved in decaf, based on the published evidence:
- Type 2 diabetes risk reduction — both caffeinated and decaffeinated coffee show inverse association with T2D incidence in pooled analyses (Salazar-Martinez 2004, van Dam 2006). The decaf effect is slightly weaker than caffeinated (roughly 6% vs 9% relative risk reduction per cup/day) but clearly present. The CGA-mediated postprandial glucose attenuation accounts for most of this.
- Hepatic protection (NAFLD, fibrosis, hepatocellular carcinoma) — meta-analyses find similar protective effects for caffeinated and decaffeinated coffee, suggesting the active mechanism is largely non-caffeine. See the Remedies/Coffee/Benefits liver-related pages.
- Type 2 diabetes-associated cardiovascular risk reduction — partially preserved in decaf.
- Anti-inflammatory effects measured by CRP and IL-6 — partially preserved.
- Gut microbiome support (Bifidobacterium enrichment, butyrate production) — preserved in decaf, as melanoidins and CGAs are the active mechanisms.
- Mild blood pressure benefit (with chronic CGA exposure) — preserved and arguably more visible in decaf since the caffeine pressor effect that obscures it in regular coffee is removed.
- Polyphenol-mediated effects on endothelial function — preserved.
- Niacin and trigonelline-derived metabolite delivery — preserved.
- Modest cerebral blood flow improvement — partially preserved (CGAs are mild cerebral vasodilators).
- Iron-binding effect on non-heme iron absorption — fully preserved (melanoidin-mediated). This is mostly a negative for iron-deficient drinkers and only relevant for separating coffee from iron-rich meals.
The summary: most CGA- and melanoidin-mediated benefits are preserved. The decaf drinker gets approximately 80% of the polyphenol-driven benefit of the regular-coffee drinker, with essentially none of the caffeine load.
Benefits That Do Not Survive Decaffeination
The following benefits depend on caffeine and are largely lost in decaf:
- Cognitive alertness and vigilance improvement — almost entirely caffeine-mediated. Decaf produces a small placebo and CGA-cerebral-blood-flow effect but nothing approaching the caffeine effect.
- Reaction time improvement — caffeine-dependent.
- Ergogenic / exercise performance benefits — almost entirely caffeine-mediated. Decaf is not an ergogenic aid.
- Mood elevation — partially caffeine-mediated (the adenosine antagonism contributes); some social/ritual mood effect of warm beverage preserved.
- Parkinson's disease risk reduction — mostly caffeine-mediated. Decaf shows much weaker or absent protection in most cohort studies, although a few find some residual effect (possibly EHT-mediated).
- Headache and migraine abortive effect — caffeine-mediated via cerebral vasoconstriction. Decaf cannot substitute for caffeine in the standard Excedrin-style migraine management.
- Acute blood pressure pressor effect — caffeine-mediated. This is generally a benefit of decaf in hypertensive patients (the pressor effect is removed), although it means decaf does not produce the temporary cognitive lift that the pressor effect partially mediates.
- Diuretic effect — caffeine-mediated. Decaf is essentially non-diuretic.
- Suppression of appetite — modestly caffeine-mediated. Most appetite-suppression benefit is lost in decaf.
- Adenosine-mediated late-day "second wind" — caffeine-specific.
The summary: cognitive and performance benefits require caffeine and are largely lost in decaf. Long-term metabolic and hepatic benefits largely survive. The choice between caffeinated and decaf is therefore aligned with what the drinker wants from the cup — alertness and performance vs polyphenol intake and ritual.
Decaf in Pregnancy
ACOG and most national obstetric societies recommend limiting caffeine to under 200 mg/day during pregnancy. The CARE study (Pickering 2008) and subsequent observational research found that caffeine intake above 200 mg/day was associated with low birth weight and increased risk of pregnancy loss in a dose-dependent fashion, with no clear threshold below 200 mg/day.
Practical implications for pregnant women who want coffee:
- Two 8-oz cups of regular drip coffee approach or exceed the 200 mg threshold. Most pregnant women who continue regular coffee need to limit to 1-2 cups/day.
- Decaf is well within the limit even at 4-6 cups/day. A pregnant woman who switches to decaf does not need to think about caffeine intake at typical consumption levels.
- Caffeine half-life is dramatically prolonged in pregnancy, particularly the third trimester (10-12 hours vs 5 hours non-pregnant), due to reduced CYP1A2 activity and increased plasma protein binding. The same morning cup that clears by evening in a non-pregnant woman remains circulating overnight in a third-trimester pregnant woman. Switching to decaf eliminates this complication.
- Decaf preserves the polyphenol benefits (relevant for gestational diabetes risk reduction, where the CGA effect on glucose absorption is potentially helpful). The 2-15 mg residual caffeine in decaf is well below the conservative pregnancy threshold.
- The methylene chloride concern in decaf, if it concerns the pregnant patient, can be addressed by choosing Swiss Water or CO2 process decaf. There is no specific evidence that the trace methylene chloride residue in conventional decaf is harmful in pregnancy, but the avoidance is reasonable on precautionary grounds.
Practical recommendation: pregnant women who drink coffee should consider switching to Swiss Water Process or CO2-process decaf throughout pregnancy, possibly with a single morning regular cup if cognitive alertness is needed (provided total caffeine stays under 200 mg/day). The polyphenol intake is preserved; the caffeine concern is essentially eliminated.
Decaf for Sleep Disorders and Anxiety
Insomnia, anxiety, and panic disorder patients are often advised to limit or eliminate caffeine. The clinical decisions:
- Mild insomnia: switch to decaf after noon; morning regular coffee usually fine. The 10-12 hour residual caffeine from morning intake is the most common iatrogenic insomnia driver and is often missed by patients who think their morning cup "does not bother me at night."
- Severe insomnia or unresponsive to other interventions: full caffeine elimination (decaf throughout the day, or no coffee at all) for 2-4 weeks to assess effect on sleep. Most patients see meaningful improvement; some find decaf alone is sufficient and a small morning regular cup can be reintroduced.
- Anxiety disorder without panic: trial of decaf for 2-4 weeks; many patients find substantial improvement in baseline anxiety. If decaf does not relieve the anxiety, the caffeine was probably not the dominant driver.
- Panic disorder: full caffeine elimination is typically recommended. Even decaf occasionally triggers symptoms in highly sensitive panic-disorder patients, though usually 2-5 mg of residual caffeine is well below the threshold for panic provocation.
- Restless legs syndrome: caffeine commonly aggravates symptoms. Switch to decaf or eliminate.
- Bruxism (tooth grinding): caffeine can worsen bruxism in sleep. Switch to decaf after noon.
See our Insomnia page and Anxiety page for more comprehensive management. The decaf switch is one of the highest-leverage, lowest-cost interventions for both conditions and is often skipped in clinical practice.
Decaf for Hypertension, Arrhythmia, and Slow Metabolizers
The cardiovascular benefit-vs-harm of regular coffee depends substantially on CYP1A2 genotype (see Cognitive Performance page for the gene-environment interaction story). For slow metabolizers and people with specific cardiovascular conditions, decaf is the safer default:
- Stage 1 hypertension: not an absolute contraindication to regular coffee, but the acute pressor effect of 5-10 mmHg is potentially clinically relevant in patients on the borderline of treatment threshold. Switching to decaf removes the pressor effect while preserving the CGA-mediated mild antihypertensive effect — the net is typically a 3-7 mmHg systolic reduction in patients who switch.
- Stage 2 hypertension or refractory hypertension: decaf is the preferred choice. Patients on multiple antihypertensives can usually tolerate one morning regular cup if motivated, but decaf throughout the rest of the day reduces the cumulative pressor load.
- Slow CYP1A2 metabolizers (rs762551 AC/CC): epidemiologically associated with increased MI risk at higher coffee intake. Switch to decaf is the prudent choice for any slow metabolizer who otherwise drinks more than ~2 cups/day of regular coffee.
- Atrial fibrillation: data are mixed; most studies find no significant association between coffee intake and AF incidence or recurrence. For AF patients who notice symptom triggering from coffee, switch to decaf.
- SVT, frequent PVCs/PACs: caffeine commonly triggers symptoms in sensitive patients. Switch to decaf.
- Long QT syndrome and recurrent syncope: caffeine is generally permitted but the autonomic effects can complicate. Decaf is often advised in patients with recurrent presentations.
For cardiovascular patients, the decaf decision is usually about removing the acute caffeine pressor and sympathetic activation effects while preserving the long-term polyphenol-driven cardiometabolic benefits. The result is a beverage choice that is essentially all upside and no downside for most cardiovascular patients.
The Half-Caf Strategy
For drinkers who want some caffeine effect but less total exposure, the "half-caf" approach blends regular and decaf in roughly 50/50 ratio — either by pre-mixed whole bean (sold by many roasters), by alternating cups, or by literally adding decaf to a partly-poured cup of regular.
Practical math: a half-caf cup delivers 40-100 mg of caffeine (half the 80-200 mg of regular) plus most of the polyphenol content of a regular cup (slightly more than half, since both regular and decaf contain CGAs). For a person who wants the alertness lift without exceeding 200 mg/day, three half-caf cups deliver 120-300 mg of caffeine spread across the day — manageable for most adults.
The half-caf approach is particularly useful for:
- Tapering off regular coffee toward decaf over weeks (gradually shift the ratio toward decaf to minimize withdrawal headache)
- Pregnant women in early pregnancy who want some caffeine effect but need to stay under 200 mg/day
- Slow CYP1A2 metabolizers who want more than just morning regular without sleep disruption
- People who notice anxiety, palpitations, or tremor from full regular intake but find decaf unsatisfying
- Late-afternoon cups when full caffeine would disrupt sleep
Most major specialty roasters offer half-caf blends; many coffee shops will prepare half-caf espresso drinks on request. The price is typically the same as regular (the decaf component is more expensive but the blending evens it out).
Key Research Papers
- Heaton K, Hyland JM, McAlpine CC, Mast JD (1989). The decaffeination process. Food Technology. — PubMed
- Salazar-Martinez E et al. (2004). Coffee consumption and risk for type 2 diabetes mellitus. Annals of Internal Medicine. — PubMed
- van Dam RM, Hu FB (2005). Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA. — PubMed
- Saab S et al. (2014). Impact of coffee on liver diseases: a systematic review. Liver International. — PubMed
- Pickering MD et al. (2008). Maternal caffeine intake during pregnancy and risk of fetal growth restriction (CARE Study). BMJ. — PubMed
- Riksen NP, Smits P, Rongen GA (2009). The cardiovascular effects of methylxanthines. Handbook of Experimental Pharmacology. — PubMed
- Klatsky AL et al. (2011). Coffee, caffeine, and risk of hospitalization for arrhythmias. Permanente Journal. — PubMed
- Ascherio A et al. (2001). Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Annals of Neurology. — PubMed
- Bhupathiraju SN et al. (2014). Changes in coffee intake and subsequent risk of type 2 diabetes: three large cohorts. Diabetologia. — PubMed
- Jee SH et al. (1999). The effect of chronic coffee drinking on blood pressure: a meta-analysis. Hypertension. — PubMed
- Chu YF et al. (2009). Roasted coffees high in lipophilic antioxidants and chlorogenic acid lactones are more neuroprotective. Journal of Agricultural and Food Chemistry. — PubMed
- Stiernet M et al. (2018). Decaffeination methods: review of solvent and water-based processes. Food Science Reviews. — PubMed
PubMed Topic Searches
- PubMed: Decaf coffee T2D
- PubMed: Decaf coffee liver
- PubMed: Coffee in pregnancy
- PubMed: Decaffeination process comparison
- PubMed: Methylene chloride safety